The global sleep software market valued at US$ 776.2 Million in 2023, is forecasted to grow at a robust CAGR of 10.1%, reaching US$ 878.9 Million in 2024 and an impressive US$ 1,569.2 Million by 2030.

The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...

An 8-week weight loss and lifestyle intervention improved vitamin D levels up to 6 months after treatment among men with OSA and high BMI.

The global sleep apnea devices market is set to expand at a steady CAGR of 9.5%, growing from USD 8.2 billion in 2023 to USD ...

On today’s CT BUZZ, Host Natasha Lubczenko sat down with Dr. Zach Korwin, owner of Sleep Stratford, to discuss an innovative ...

For patients with obstructive sleep apnea (OSA), sleep surgery is associated with a significantly reduced risk for motor ...

According to statistics by the American Association of Medicine, the disorder sleep apnea affects approximately 30 million US ...

Taking a GLP-1 may help treat sleep apnea since obesity is one of many factors that increases your likelihood of the sleep ...

Key Takeaways Untreated sleep apnea contributes to car crashesPatients who got no treatment were 21% more likely to be in a ...

The good news is that research also concluded that treatment with a CPAP machine can help. ICE arrests more than 530 migrants ...

Tom Castaneda from South Texas Health Systems discusses Sleep apnea on the upcoming episode of STHS TV on NBC 23. This ...